SDHB-related metastatic paragangliomas treated with capecitabine and temozolomide: Experience of a tertiary centre

#4385

Introduction: SDHB pathogenic variants predispose to aggressive and metastatic paragangliomas (mPGLs). International consensus recommends temozolomide treatment (low-grade evidence). Capecitabine and temozolomide (CAPTEM) has shown advantage over temozolomide in the treatment of neuroendocrine tumours (NETs). Evidence for its use in mPGLs remains scarce.

Aim(s): To evaluate CAPTEM treatment in SDHB-related mPGLs.

Materials and methods: Retrospective review of SDHB-related mPGLs cases treated with CAPTEM over the past 20 years, analysing patient and disease characteristics and efficacy of CAPTEM treatment.

Conference:

Presenting Author: G. Martins R

Authors: Silva L, Martins R, Couto J, Garcia R, Martins Fernandes A,

Keywords: mPGL, SDHB, captem,